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Introduction: Metastases are detected in 20% of patients with solid tumours at diagnosis and a further 30% after
diagnosis. Radiation therapy (RT) has proven effective in bone (BM) and brain (BrM) metastases. The objective of
this study was to analyze the variability of RT utilization rates in clinical practice and the accessibility to medical
technology in our region.
Patients and methods: We reviewed the clinical records and RT treatment sheets of all patients undergoing RT for
BM and/or BrM during 2007 in the 12 public hospitals in an autonomous region of Spain. Data were gathered on
hospital type, patient type and RT treatment characteristics. Calculation of the rate of RT use was based on the
cancer incidence and the number of RT treatments for BM, BrM and all cancer sites.
Results: Out of the 9319 patients undergoing RT during 2007 for cancer at any site, 1242 (13.3%; inter-hospital
range, 26.3%) received RT for BM (n = 744) or BrM (n = 498). These 1242 patients represented 79% of all RT
treatments with palliative intent, and the most frequent primary tumours were in lung, breast, prostate or digestive
system. No significant difference between BM and BrM groups were observed in: mean age (62 vs. 59 yrs,
respectively); gender (approximately 64% male and 36% female in both); performance status (ECOG 0–1 in 70 vs.
71%); or mean distance from hospital (36 vs. 28.6 km) or time from consultation to RT treatment (13 vs. 14.3 days).
RT regimens differed among hospitals and between patient groups: 10 × 300 cGy, 5 × 400 cGy and 1x800cGy were
applied in 32, 27 and 25%, respectively, of BM patients, whereas 10 × 300cGy was used in 49% of BrM patients.
Conclusions: Palliative RT use in BM and BrM is high and close to the expected rate, unlike the global rate of RT
application for all cancers in our setting. Differences in RT schedules among hospitals may reflect variability in
clinical practice among the medical teams.
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Cancer remains a major health and social problem.
Therapeutic advances over the past decade have pro-
duced important improvements in cancer control and in
the survival of cancer patients, and a better management
of their symptoms has enhanced their quality of life [1].
Progress has been made in surgery, chemotherapy and
radiation therapy (RT) and in their greater coordination
in a multidisciplinary approach [2].
It is estimated that around 20% of patients with solid
tumours are diagnosed after the spread of the disease* Correspondence: jose.exposito.sspa@juntadeandalucia.es
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reproduction in any medium, provided the orand a further 30% develop metastases at some time after
the diagnosis [3]. Treatment for patients with metastases
is usually with palliative intent and focuses on the con-
trol of symptoms and the maximization of symptom-free
time. Metastases are most frequently localized in bone,
brain, lung and liver and usually derive from primary
tumours in breast, prostate, colon/rectum and lung, i.e.,
the most frequent solid tumours [1].
As in primary tumours, the best outcomes in metastatic
cancer are obtained by adopting a multidisciplinary
approach. The use of RT in this setting is supported by
considerable and robust evidence. It is considered one of
the most effective and cost-effective treatments in patients
with bone (BM) or brain (BrM) metastases [4], and pal-
liative RT represents around 10-20% of the total work-
load in a typical radiotherapy unit [5]. Hypofractionatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these patients, although a wide range of regimens and
combinations has been applied [6,7]. Comparative data
on RT utilization rates across different hospitals are of
interest to indicate the access of patients to this technol-
ogy, its appropriateness and the variability in medical
practice [8]. There have been reports of variations in
the use of RT for different tumours [9-11] and in the
dose schedules selected for BM and BrM among differ-
ent centres [12-16]. In our region, a previous study found
a suboptimal RT utilization rate and significant variabil-
ity in the use of RT differences among hospitals [17,18].
This finding prompted the present investigation into the
use of RT in BM and BrM, two well-established indica-
tions for this treatment.
Andalusia has a surface area of 87597Km2 and 7.8 million
inhabitants; around half (45.6%) of the population lives
within a 20 km radius around the eight cities in the re-
gion. The regional public health system provides
universal free coverage, while 10% of the total care is
delivered in private healthcare facilities. Figure 1 shows
the distribution of RT departments in the region.
This study focuses on the RT utilization rate and the
patterns of palliative RT application in patients with BM
and BrM. It is part of a broader investigation (Variability
and Appropriateness of Radiotherapy in Andalusia
[VARA] projects I and II) into the quality of RT deliv-
ered in 12 public hospitals in the Andalusian public
health system [17].Figure 1 Location of radiotherapy departments in Andalusia. TC – Tor
Hospital (Granada). SC - San Cecilio University Hospital (Granada). J - Jaén H
CH - Carlos Haya University Hospital (Málaga). VV - Virgen de la Victoria Un
Cádiz). PM - Puerta del Mar University Hospital (Cádiz). VM - Virgen del Roc
University Hospital (Sevilla). JRJ - Juan Ramón Jiménez Hospital (Huelva).Patients and methods
This retrospective longitudinal study included all public
hospitals in Andalusia (Spain) equipped with RT devices
(n = 12, H1-H12); the study period was from January 1
to December 31 2007; data were gathered on all patients
treated with external RT for BM or BrM, including
details of all palliative RT treatments. Patients were
identified from the clinical management computer
system linked to the RT equipment (VarisW, lantisW or
ImpacW Departmental networks) and from the hospitals’
admission records. The same sources were used to
gather data on all patients irradiated in any cancer
site during the study period. Clinical records and RT
sheets were reviewed by specifically trained researchers.
When errors or incongruous results were detected, a
second review was performed by another member of
the research team.
Data were gathered on the type of hospital and RT
unit and on the demographic and clinical characteristics
and RT treatments of the patients. Study variables
included characteristics of the hospital (province), patient
(age, gender, type [brain/bone], performance status with
Eastern Cooperative Oncology Group [ECOG] scale or
Karnofsky scale and primary tumour site), and treatment
(medical indication: total doses, fractions, delay after
decision, radiosurgery/surgery in brain metastasis, and
adverse effects [acute grade 2-3 toxicity]). The distance
from RT facilities was based on the area code directory.
Because of the difficulty of identifying all patients inrecárdenas Hospital (Almería). VN - Virgen de las Nieves University
ospital (Jaén). RS - Reina Sofía University Hospital (Córdoba).
iversity Hospital (Málaga). PE - Punta de Europa Hospital (Algeciras,
ío University Hospital (Sevilla). VR - Virgen de la Macarena
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estimate the total number. We calculated that palliative
RT treatment would be indicated in 1576 patients, based
on the cancer incidence of 28144 cases/year [19] and
assuming an RT rate (irradiated cases divided by diag-
nosed cancer cases) of 28%, following VARA I criteria
[17,18], and that 20% of RT treatments would be pallia-
tive treatments for BM and BrM [20]. We also estimated
the percentage of RT candidates per hospital. Toxicity
data were retrospectively gathered from clinical records.
Statistical procedures
Descriptive outcomes are shown as means, medians,
standard deviations and confidence intervals. The chi-
square test was used for the comparison of independent
qualitative variables.
Results
During 2007, 1242 patients underwent RT for BM
(n= 744) or BrM (n = 498), i.e., 13.4% (inter-hospital
range, 5-26.3%) of all patients receiving RT (9310 cases)
in the 12 hospitals in the study. These 1242 patients
represented 79% of the 1576 patients with BM or BrM
estimated to be candidates for palliative RT. The charac-
teristics of the patients are reported in Table 1. Mean
age was 62 yrs in BM patients and 59 yrs in BrM
patients; the sex distribution was similar in both groups
(63% male, 37% female).
Bone metastases (BM)
The primary tumour was lung, breast and prostate in
30.8, 24.6 and 14.3% of BM cases, respectively. In more
than two-thirds of cases (79%), BM were in pelvis and
vertebra (cervical 7.5%, dorsal 75.5% and lumbar 17%).
Patients had varying degrees of medullary compression,
while the Eastern Cooperative Oncology Group (ECOG)
performance status was 0–1 in 70% of the patients at the
start of RT.
Patients lived at a mean distance of 36 Km (95% CI
27–44) from the hospital. The mean delay from radi-
ation unit consultation to RT initiation was 13 days
(95% CI 10–15); this delay was 3 days for patients with
spinal cord injury, and it was ≤ 7 days in 45% of all BM
patients [Tables 2, 3]. RT was an outpatient treatment in
73% of these patients; 53% of treatments were on a
Monday or Friday.
Computed tomography (CT)-based planning was per-
formed before RT in 88% of cases. The megavoltage
machine was a Co60 unit in 42.9% of cases. Grade 2–3
toxicity was observed in 13% of patients [Table 4].
A mean of 8% of all RT treatments were for BM, with
significant (p < 0.005) inter-hospital differences in this
percentage, which ranged from 2.8% in H1 to 16.3% inH9 [Table 5]. The mean distance between residence and
hospital was significantly higher in two hospitals (H5
and H8) than in the rest, and significantly longer delays
before RT were found in two hospitals (H5 and H10).
The mean total RT dose was 22.3 Gy (range 5-44 Gy)
and the median was 30 Gy. The regimen was
10 × 300cGy in 32% of cases, 5 × 400 cGy in 27% and
1 × 800 cGy in 25% [Table 4].
There were significant (p < 0.0005) inter-hospital dif-
ferences in the regimens prescribed for these patients
[Table 6]: 10 × 300cGy was used by four hospitals (H2,
H3, H4, H6 and H12), 5 × 400 by two hospitals (H1 and
H10) and 1 × 800cGy by the other three hospitals (H5,
H7 and H11).
Table 2 Distance to RT unit and delays
Bone Metastasis Brain Metastasis
Distance (Km)
Range 0–365 0– 46
Mean (95%CI) 36 (27–44) 28 (22–35)
Median 21 22
Delays (days)
Range 0– 50 0–67
Mean (95%CI) 13 (10–15) 14 (12–17)
Median 8 10
Delays (%)
< 7 days 65% 45%




Table 4 Treatment features
Bone M Brain M
Doses (Gy)
Range (5–44) (18–32)
Mean (95%CI) 22 (21–24) 23 (21–24)
Median 30 20
Dose fraction:
10 × 300 cGy 32% 58%
5× 400 cGy 27% 20%
1× 800 cGy 25% 3%
15× 200 cGy 2% 19%







LA 6 Mv 13% 1%
LA≥ 15 Mv 44% 51%
Toxicity grade 2-3 13% 15%
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The primary tumour was in the lung (56%), breast (20%)
or digestive system (8%). Performance status was ECOG
0–1 in 71% of BrM patients. These patients lived at a
mean distance of 28.5 Km (95% CI 22–35) [Tables 1,2].
The mean delay from first consultation to RT was 14.3
days (95% CI 11.5-17.19 d), and it was ≤7 days in 45% of
cases [Table 3]. RT was an outpatient treatment in 56%
of cases. Stereotactic radiosurgery was carried out in 16
patients (3.2%) and surgery in 12 (2.4%).
CT-based planning was performed in 79% of cases. A
mean of 5.34% of all RT treatments were for BrM, withTable 3 Comparison of hospitals: delay from radiation
unit consultation to radiotherapy initiation
H D BM (TD) D BrM (TD)
1 8.63 (6.12) 7 (11.68)
2 11.45 (6.92) 7.45 (5.47)
3 9.15 (13.35) 9.90 (13.12)
4 9.16 (11.73) 13 (7.41)
5 13,10 (16.81) 20.36 (10.99)
6 - -
7 10.21 (11.48) 4.81 (4.19)
8 8.23 (18.10) 4.44 (6.45)
9 6.02 (6.41) 4.93 (4.49)
10 13.15 (20.87) 6.85 (16.58)
11 3.70 (8.83) 5.88 (11.60)
12 2.55 (9.89) 6.60 (20.97)
T 8.27 (12.55) 7.93 (11.91)
H=Hospital.
D BM=mean delay (days) from RT unit consultation to RT initiation for Bone M.
D BrM=mean delay (days) from RT unit consultation to RT initiation for BrM.
TD= typical deviation.significant (p < 0.005) inter-hospital differences in this
percentage, which ranged from 2.6% in H1 to 10.9% in
H2 [Table 5]. Again, the mean distance between resi-
dence and hospital was significantly longer in H5 and
H8 and the delay to RT initiation was significantlyTable 5 Comparison of hospitals: irradiation rate
H RTcases RT BM(*) RT BrM(*) RT BM+BrM
1 458 2.8% 2.6% 5.4%
2 128 13.2% 10.9% 24.1%
3 1081 6.8% 6.2% 13%
4 1111 8.5% 3.8% 12.3%
5 827 6.2% 4.2% 10.4%
6 430 8.4% 7.9% 16.2%
7 634 14% 4.7% 23.6%
8 541 4.9% 6% 10.9%
9 698 16.3% 10% 26.3%
10 999 6.45% 4.2% 10.6%
11 1647 7.6% 5.2% 13%
12 765 4.8% 4.2% 5%
T 9319 8% 5.4% 13.4%
Mean 14.6%
(*) Statistical significance: p < 0.005.
H =Hospital. RT = Radiotherapy. BM=Bone Metastases. BrM=Brain metastases.
RT BM=percentage of cases treated by RT for BM.
RT BrM=percentage of cases treated by RT for BrM.
Table 6 RT schemes used in Bone Metastases by hospital*
H 1× 800cGy 5× 400 cGy 10×300cGy Others Total
1 8 5 13
61.5% 38.5%
2 2 14 1 17
11.8% 82.3% 5.9%
3 12 8 45 9 74
16.2% 10.8% 60.8% 12.2%
4 3 12 63 16 94
3.2% 12.8% 67% 17%
5 36 14 2 52
69.3% 26.9% 3.8%
6 2 6 24 4 36
5.6% 16.7% 66.7% 11%
7 57 20 7 6 90
63.3% 22.2% 7.8% 6.7%
8 1 5 1 20 27
3.7% 18.5% 3.7% 74.1%
9 16 36 8 54 114
14% 31.6% 7% 47.4%
10 9 31 20 4 64
14.1% 48.4% 31.3% 6.3%
11 44 46 26 10 126
34.9% 36.6% 20.6% 7.9%
12 4 8 25 37
10.8% 21.6% 67.6%
T 184 196 240 124 744
24.7% 26.3% 32.3% 16.7%
* Statistical significance: p < 0.0005.
Table 7 RT schemes used in Brain Metastases by
hospital*
H 3× 600cGy 5× 400 cGy 10× 300cGy Others Total
1 3 8 1 12
25% 66.7% 8.3%
2 13 1 14
92.9% 7.1%
3 58 9 1 68
85.3% 13.2% 1.5%
4 1 2 38 1 42
2.4% 4.7% 90.5% 2.4%
5 35 35
100%
6 28 6 34
82% 18%
7 24 1 5 30
80% 3.3% 16.7%
8 22 10 1 33
66.7% 30.3% 3%
9 10 53 5 1 69
14.5% 76.8% 7.3% 1.4%
10 41 1 42
97.6% 2.4%




T 93 138 246 21 498
18.7% 27.7% 49.4% 4.2%
* Statistical significance: p < 0.001.
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interhospital differences in the regimens prescribed for
these patients [Table 7], with 10 × 300cGy being used by
seven hospitals (H1, H2, H4, H5, H6, H11 and H12) and
3 × 600 cGy by two (H3 and H7).
The mean total RT dose was 22.9 (range 21–24) and
the median was 20 Gy. The schedule was 10 × 300 cGy
in 49% of cases and 5 × 400cGy in 28% [Table 4].
The distance from residence to hospital was not asso-
ciated with the treatment rate or the delay to RT in ei-
ther group of patients.
Discussion
Novel therapeutic approaches have improved the sur-
vival of cancer patients, including some with metastases
from solid tumours, thereby increasing the demand for
palliative RT. The effectiveness of external RT has been
widely demonstrated [4,20], and it has been estimated
that around 50% of patients with newly diagnosed cancerand 10-20% of relapsed patients are suitable candidates
for palliative RT [21,22].
Studies on variations in medical practice are valuable
to assess the quality of care and clinical practice [23] but
few have been published in the field of oncology. They
are generally used to compare treatments among geo-
graphical areas [24,25] or to survey medical opinions
on specific treatment options for hypothetical clinical
scenarios [15,26], and both types of study have revealed
a substantial variation in cancer care. A high variability
in cancer treatment outcomes has also been highlighted
in reports from the EUROCARE programme [27].
Limitations of this study include the relatively short
time period considered and the sources of information,
with some missing data (see Tables), although the fact
that data were gathered from a direct review of clinical
records and treatment sheets is a study strength. Finally,
it was necessary to estimate the number of potential
Expósito et al. Radiation Oncology 2012, 7:131 Page 6 of 7
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our estimation was slightly lower than that reported by
Nieder et al. [5].
The distribution of clinical variables and tumour sites
in the cancer patients in these hospitals was similar to
previous international reports [28]. Although the hospi-
tals in this study were all referral centres for RT, the
mean distance from the patient’s home to the RT unit
was shorter than in other studies [29]. If the results
for two of the hospitals (H5 and H10) are excluded, the
median delay from first consultation to RT initiation
was 13 days, which can be considered acceptable [8,20].
Treatment schedules varied widely among centres
[Tables 6,7], consistent with previous reports in different
countries [12-16].
The observed treatment rate was slightly lower than
the expected rate but was higher than our group found
for other cancer sites [9,18], indicating a greater confi-
dence about the use of RT with palliative rather than
radical or curative intent. RT with palliative intent repre-
sented 14% of all patients undergoing RT, but the hospi-
tals varied widely and significantly in the selection of
treatment regimen. The reasons for this variation are
not clear and warrant further investigation, although dif-
ferences in case mix or in the number of patients receiv-
ing adjuvant or radical RT may play a role.
According to our findings, the same type of clinical
situation is treated with very different doses (total and
per fraction) in our region. This is a frequent observa-
tion in BM therapy [12,30] and appears to be more
related to the clinical care pattern established in RT
units rather than to effectiveness or clinical criteria. In
BM patients, the frequency of the standard 1x800 cGy
scheme, which is supported by well-conducted studies
[16,31-33], was strikingly low (25%).
In conclusion, the rate of palliative RT use for BM and
BrM in these hospitals was close to published reports,
unlike the use of RT for other clinical purposes. More-
over, the delay before RT initiation was relatively low,
and the overall rate of RT utilization appears to have
been adequate. However, there was a variation in treat-
ment schedules among hospitals that requires further
investigation and suggests a need to develop protocols
and training programmes to standardize and improve
the care of these patients in our setting.
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